314 related articles for article (PubMed ID: 35055124)
1. The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.
Miyashiro D; Souza BCE; Torrealba MP; Manfrere KCG; Sato MN; Sanches JA
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055124
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
[TBL] [Abstract][Full Text] [Related]
3. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
[TBL] [Abstract][Full Text] [Related]
4. Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course.
Wu R; Zippin JH; Magro C
Cutis; 2014 Feb; 93(2):E18-25. PubMed ID: 24605355
[TBL] [Abstract][Full Text] [Related]
5. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA.
Ni X; Richmond HM; Liao XM; Decker WK; Shiue LH; Shpall EJ; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2631-2639. PubMed ID: 18480841
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.
Fierro MT; Comessatti A; Quaglino P; Ortoncelli M; Osella Abate S; Ponti R; Novelli M; Bernengo MG
Dermatology; 2006; 213(4):284-92. PubMed ID: 17135733
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and Helios Are Highly Expressed on CD4
Jariwala N; Benoit B; Kossenkov AV; Oetjen LK; Whelan TM; Cornejo CM; Takeshita J; Kim BS; Showe LC; Wysocka M; Rook AH
J Invest Dermatol; 2017 Jan; 137(1):257-260. PubMed ID: 27592800
[No Abstract] [Full Text] [Related]
9. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
10. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
11. Immunologic differentiation of the Sézary syndrome due to cutaneous T-cell lymphoma and chronic actinic dermatitis.
Chu AC; Robinson D; Hawk JL; Meacham R; Spittle MF; Smith NP
J Invest Dermatol; 1986 Feb; 86(2):134-7. PubMed ID: 3528307
[TBL] [Abstract][Full Text] [Related]
12. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
[TBL] [Abstract][Full Text] [Related]
13. CD7-positive Sézary syndrome with a Th1 cytokine profile.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):368-74. PubMed ID: 8655729
[TBL] [Abstract][Full Text] [Related]
14. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
[TBL] [Abstract][Full Text] [Related]
15. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome).
Vonderheid EC; Bigler RD; Kotecha A; Boselli CM; Lessin SR; Bernengo MG; Polansky M
J Invest Dermatol; 2001 Sep; 117(3):654-62. PubMed ID: 11564173
[TBL] [Abstract][Full Text] [Related]
16. Rapid progression of immune dysregulation in an HIV-infected patient with Sézary syndrome.
Dadoo AS; Steenkamp I
Dermatol Online J; 2019 Jan; 25(1):. PubMed ID: 30710903
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous IL-8 production by CD4(+), CD7(+) leukemia cells in erythrodermic Sézary syndrome.
Ogawa F; Shimizu K; Hamasakia Y; Tanaka Y; Katayama I; Yamada Y; Tomonaga M
Leuk Lymphoma; 2002 May; 43(5):1061-6. PubMed ID: 12148887
[TBL] [Abstract][Full Text] [Related]
18. Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.
Jiang TT; Kruglov O; Akilov OE
Blood Adv; 2024 May; 8(10):2384-2397. PubMed ID: 38489234
[TBL] [Abstract][Full Text] [Related]
19. mu-Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome.
Bénard A; Cavaillès P; Boué J; Chapey E; Bayry J; Blanpied C; Meyer N; Lamant L; Kaveri SV; Brousset P; Dietrich G
J Invest Dermatol; 2010 May; 130(5):1337-44. PubMed ID: 20107485
[TBL] [Abstract][Full Text] [Related]
20. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.
Harro CM; Perez-Sanz J; Costich TL; Payne KK; Anadon CM; Chaurio RA; Biswas S; Mandal G; Rigolizzo KE; Sprenger KB; Mine JA; Showe LC; Yu X; Liu K; Rodriguez PC; Pinilla-Ibarz J; Sokol L; Conejo-Garcia JR
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33270606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
